<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319328</url>
  </required_header>
  <id_info>
    <org_study_id>H2019:031</org_study_id>
    <nct_id>NCT04319328</nct_id>
  </id_info>
  <brief_title>Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?</brief_title>
  <official_title>Pharmacokinetic Evaluation of Cefazolin, Ceftazidime, and Ciprofloxacin in Chronic Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Kidney Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to optimize the dosing of cefazolin, ceftazidime, and ciprofloxacin for
      patients on high-flux hemodialysis. For each antibiotic 20 participants will be enrolled and
      three blood samples will be collected from each participant. Antibiotic levels will be
      measured in each blood sample. This data will be used to develop population-pharmacokinetic
      models for each antibiotic. Finally, Monte Carlo simulations will be used to develop
      evidence-based dosing recommendations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to optimize the dosing of three commonly used antibiotics, thereby
      improving the treatment of serious, often life-threatening infections in patients on
      intermittent high-flux hemodialysis (iHFHD).

      The hypothesis is that current antibiotic dosing is suboptimal, thereby increasing the risk
      of poor outcomes including treatment failure, adverse drug reactions and antibiotic
      resistance.

      A prospective, non-interventional pharmacokinetic (PK) study of cefazolin, ceftazidime, and
      ciprofloxacin will be conducted in the St. Boniface Hospital outpatient hemodialysis unit.

      The 1st objective of this study is to measure the free and total plasma concentrations of
      cefazolin, ceftazidime, and ciprofloxacin in adult patients on iHFHD and receiving antibiotic
      therapy for suspected or proven infection. For each antibiotic 20 participants will be
      enrolled and three blood samples will be collected from each participant. Antibiotic
      concentrations will be measured using an ultra high performance liquid chromatograph mass
      spectrometer. Total antibiotic concentrations in plasma will be measured in all patient
      samples. To describe protein binding, free levels will also be measured in the first two
      samples collected from the first 10 patients for each antibiotic.

      The 2nd objective of this study is to characterize the PK of cefazolin, ceftazidime, and
      ciprofloxacin in patients on iHFHD using population-PK modelling. Covariates with potential
      influence on PK such as gender, age, body weight, dialyzer type, blood and dialysate flow
      rates, duration of dialysis and Kt/Vurea will be investigated, and incorporated as
      appropriate. For each antibiotic, the best PK model will be selected using established
      goodness-of-fit tests, and then independently validated.

      The 3rd objective of this study is to translate findings to patient care using Monte Carlo
      simulations to evaluate conventional antibiotic dosing and develop optimized evidence-based
      dosing recommendations for cefazolin, ceftazidime, and ciprofloxacin in patients on iHFHD.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of distribution (Vd) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.</measure>
    <time_frame>48 to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug elimination (ke) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.</measure>
    <time_frame>48 to 72 hours</time_frame>
    <description>Drug elimination (ke) during and between dialysis sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug clearance (CL) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.</measure>
    <time_frame>48 to 72 hours</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Hemodialysis Complication</condition>
  <condition>Infectious Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <description>n = 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftazidime</arm_group_label>
    <description>n = 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <description>n = 20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Non-interventional pharmacokinetic evaluation</description>
    <arm_group_label>Cefazolin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <description>Non-interventional pharmacokinetic evaluation</description>
    <arm_group_label>Ceftazidime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Non-interventional pharmacokinetic evaluation</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients on chronic intermittent high-flux hemodialysis being treated for infection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old

          -  Proven or suspected infection

          -  Receiving cefazolin, ceftazidime, or ciprofloxacin for treatment

          -  Treatment course allows for collection of three 6 mL blood samples as per protocol

        Exclusion Criteria:

          -  Chronic liver disease, Child Pugh Class C or higher

          -  Received study drug as part of a different treatment course in 1-week preceding start
             of new treatment course

          -  Acute kidney injury or recovering kidney function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheryl A Zelenitsky, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Boniface Hospital, Outpatient Hemodialysis Unit</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Pharmacy, University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Sheryl Zelenitsky</investigator_full_name>
    <investigator_title>Professor, College of Pharmacy, Rady Faculty of Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Antibiotic Dosing</keyword>
  <keyword>Cefazolin</keyword>
  <keyword>Ceftazidime</keyword>
  <keyword>Ciprofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

